Movement Alert｜Celcuity Inc Falls 5.59% in Pre-Market Trading, FDA Approves Core Drug Triggering Sell-the-News Reaction

Market Focus07-15

On July 15, Celcuity Inc fell 5.59% in pre-market trading, trading at $104.84/share, with turnover of $90,100.

On the news front, the FDA officially approved Celcuity's core drug REVTORPYK (gedatolisib) for treating HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer, based on Phase 3 VIKTORIA-1 trial data showing median progression-free survival of 9.3 months versus 2.0 months with fulvestrant alone. However, the stock had already rallied over 5% intraday ahead of the PDUFA target date of July 17, prompting a classic sell-the-news reaction once approval was confirmed.

Additionally, the current approval is limited to PIK3CA wild-type patients only. A supplemental application for PIK3CA-mutated patients is expected to be submitted in Q3, creating a potential expectations gap regarding the scope of the approved indication. The company anticipates a commercial launch in late Q3.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155513539?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155513539","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Celcuity Inc Falls 5.59% in Pre-Market Trading, FDA Approves Core Drug Triggering Sell-the-News Reaction","media":"Market Focus","content":"<p><p>On July 15, Celcuity Inc fell 5.59% in pre-market trading, trading at $104.84/share, with turnover of $90,100.</p><p>On the news front, the FDA officially approved Celcuity's core drug REVTORPYK (gedatolisib) for treating HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer, based on Phase 3 VIKTORIA-1 trial data showing median progression-free survival of 9.3 months versus 2.0 months with fulvestrant alone. However, the stock had already rallied over 5% intraday ahead of the PDUFA target date of July 17, prompting a classic sell-the-news reaction once approval was confirmed.</p><p>Additionally, the current approval is limited to PIK3CA wild-type patients only. A supplemental application for PIK3CA-mutated patients is expected to be submitted in Q3, creating a potential expectations gap regarding the scope of the approved indication. The company anticipates a commercial launch in late Q3.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Celcuity Inc Falls 5.59% in Pre-Market Trading, FDA Approves Core Drug Triggering Sell-the-News Reaction</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Celcuity Inc Falls 5.59% in Pre-Market Trading, FDA Approves Core Drug Triggering Sell-the-News Reaction\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Celcuity Inc fell 5.59% in pre-market trading, trading at $104.84/share, with turnover of $90,100.</p><p>On the news front, the FDA officially approved Celcuity's core drug REVTORPYK (gedatolisib) for treating HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer, based on Phase 3 VIKTORIA-1 trial data showing median progression-free survival of 9.3 months versus 2.0 months with fulvestrant alone. However, the stock had already rallied over 5% intraday ahead of the PDUFA target date of July 17, prompting a classic sell-the-news reaction once approval was confirmed.</p><p>Additionally, the current approval is limited to PIK3CA wild-type patients only. A supplemental application for PIK3CA-mutated patients is expected to be submitted in Q3, creating a potential expectations gap regarding the scope of the approved indication. The company anticipates a commercial launch in late Q3.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"","article_id":"1155513539","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155513539","pubTimestamp":1784113177,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Celcuity Inc fell 5.59% in pre-market trading, trading at $104.84/share, with turnover of $90,100.On the news front, the FDA officially approved Celcuity's core drug REVTORPYK...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc"},"translate_title":"走势警报|Celcuity Inc 盘前交易下跌 5.59%，FDA 批准核心药物引发新闻抛售反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":1},"content_text":"On July 15, Celcuity Inc fell 5.59% in pre-market trading, trading at $104.84/share, with turnover of $90,100.On the news front, the FDA officially approved Celcuity's core drug REVTORPYK (gedatolisib) for treating HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer, based on Phase 3 VIKTORIA-1 trial data showing median progression-free survival of 9.3 months versus 2.0 months with fulvestrant alone. However, the stock had already rallied over 5% intraday ahead of the PDUFA target date of July 17, prompting a classic sell-the-news reaction once approval was confirmed.Additionally, the current approval is limited to PIK3CA wild-type patients only. A supplemental application for PIK3CA-mutated patients is expected to be submitted in Q3, creating a potential expectations gap regarding the scope of the approved indication. The company anticipates a commercial launch in late Q3.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155513539","isCrawlerRequest":true}